Crohn Disease

• CLINICAL_TRIALS withdrawal · 2013-03-06
  Clinical Trial Update: Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease [Phase 4]

  Phase 4 trial evaluating top-down therapy for pediatric Crohn's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2012-10-30
  Clinical Trial Update: A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease [Phase 2]

  A Phase II study of Olokizumab for Crohn's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2012-08-31
  Clinical Trial Update: Chondroitin Sulfate for Crohn's Disease [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating chondroitin sulfate for Crohn's disease was withdrawn.

• CLINICAL_TRIALS withdrawal · 2012-05-28
  Clinical Trial Update: Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas [Phase 3]

  A Phase 3 trial evaluating certolizumab for Crohn's disease with draining fistulas has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2012-05-28
  Clinical Trial Update: A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease [Phase 3]

  A Phase 3 trial evaluating the safety of chronic therapy with certolizumab pegol in Crohn's disease has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2008-03-20
  EMA Refused: Cimzia (certolizumab pegol) — UCB Pharma SA

  EMA decision refused approval for Cimzia (certolizumab pegol) for Crohn's disease. The marketing authorization application was not granted.

• EMA withdrawal · 2008-02-14
  EMA Withdrawn: Trudexa (adalimumab) — Abbott Laboratories Ltd.

  EMA has withdrawn Trudexa (adalimumab) from the market.

• EMA withdrawal · 2008-01-25
  EMA Refused: Natalizumab Elan Pharma (natalizumab) — Elan Pharma International Ltd.

  The EMA refused the marketing authorization for natalizumab from Elan Pharma International Ltd. for Crohn's disease.